Evaluation of Syracuse Healthy Start's program for abnormal flora management to reduce preterm birth among pregnant women.
Randomized trials of bacterial vaginosis (BV) treatment among pregnant women to reduce preterm birth have had mixed results. Among non-pregnant women, BV recurs frequently after treatment. Randomized trials of early BV treatment for pregnant women in which recurrence was retreated have shown promise in reducing preterm birth. Syracuse's Healthy Start (SHS) program began in 1997; in 1998 prenatal care providers for pregnant women living in high infant mortality zip codes were encouraged to screen for abnormal vaginal flora at the first prenatal visit. Vaginal swabs were sent to a referral hospital laboratory for Gram staining and interpretation. SHS encouraged providers to treat and rescreen women with bacterial vaginosis or abnormal flora (BV). We abstracted prenatal and hospital charts of live births between January 2000 and March 2002 for maternal conditions and treatments. We merged abstracted data with local electronic data. We evaluated the effect of BV screening before 22 weeks gestation, treatment, and rescreening using a retrospective cohort study design. Among 838 women first screened before 22 weeks, 346 (41%) had normal flora and 492 (59%) women had BV at a mean of 13 weeks gestation; 202 (24%) did not have treatment documented and 290 (35%) received treatment at a mean of 15 weeks gestation; 267 (92%) of those treated were re-screened. Among pregnant women with early BV, 42 (21%) untreated women and 28 (10%) treated women delivered preterm (Odds Ratio [OR] 0.4, 95% confidence interval [CI] 0.2-0.7)). After adjustment for age, race, prior preterm birth and other possible confounders, treatment remained associated with a reduced risk of preterm birth compared to no treatment (aOR = 0.5, 95% CI 0.3-0.9); the aOR for women with normal flora was not significantly different.


CONCLUSIONS
Screening, treatment, and rescreening for BV/abnormal flora between the first prenatal visit and 22 weeks gestation showed promise in reducing preterm births and deserves further study.
Koumans
Emilia H
EH
Division of STD Prevention, Centers for Disease Control and Prevention, 1600 Clifton Rd NE MS E-02, Atlanta, GA, 30333, USA. ekoumans@cdc.gov
Lane
Sandra D
SD
Aubry
Richard
R
Demott
Kathleen
K
Webster
Noah
N
Levandowski
Brooke A
BA
Berman
Stuart
S
Markowitz
Lauri E
LE
D015331:Cohort Studies; D005260:Female; D052776:Female Urogenital Diseases / Q000175:diagnosis / Q000188:drug therapy; D005865:Gestational Age; D006801:Humans; D008485:Medical Audit; D009518:New York; D011247:Pregnancy; D047928:Premature Birth / Q000209:etiology / Q000517:prevention & control*; D011295:Prenatal Care; D015397:Program Evaluation; D012189:Retrospective Studies; D016585:Vaginosis, Bacterial / Q000150:complications / Q000188:drug therapy*
BJOG. 2006 Jun;113(6):629-37
16709205
Am J Obstet Gynecol. 2006 May;194(5):1283-9
16647911
Obstet Gynecol. 2003 Mar;101(3):516-22
12636956
Clin Obstet Gynecol. 2007 Sep;50(3):652-83
17762416
N Engl J Med. 1998 Jul 30;339(5):313-20
9682045
Sex Transm Dis. 2007 Dec;34(12):954-9
18077845
Am J Obstet Gynecol. 2004 Feb;190(2):363-70
14981375
Am J Obstet Gynecol. 2007 Sep;197(3):294.e1-6
17826426
N Engl J Med. 1995 Dec 28;333(26):1732-6
7491136
Best Pract Res Clin Obstet Gynaecol. 2007 Jun;21(3):375-90
17241817
J Clin Microbiol. 1983 Jul;18(1):170-7
6193137
BMJ. 1994 Jan 29;308(6924):295-8
8124116
Acta Obstet Gynecol Scand. 1998 Jan;77(1):37-40
9492715
Prog Clin Biol Res. 1981;70:31-40
6458824
Sex Transm Dis. 2007 Nov;34(11):864-9
17621244
N Engl J Med. 1980 Oct 30;303(18):1038-41
6999345
Lancet. 2003 Mar 22;361(9362):983-8
12660054
Ann Intern Med. 2008 Feb 5;148(3):220-33
18252684
J Infect Dis. 1999 Nov;180(5):1632-6
10515826